Evidence map›Paper›PMID 37085698›Full record

ArticleScientific reports2023

Low level of HIV-1C integrase strand transfer inhibitor resistance mutations among recently diagnosed ART-naive Ethiopians.

Mulugeta Kiros, Dessalegn Abeje Tefera, Henok Andualem, Alene Geteneh, Abebech Tesfaye, Tamirayehu Seyoum Woldemichael, Eleni Kidane, Dawit Hailu Alemayehu, Melanie Maier, Adane Mihret and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Mulugeta KirosDepartment of Medical Laboratory Science, College of Medicine and Health Sciences, Aksum University, Aksum, Ethiopia. mulugetakiros@gmail.com.ORCID 0000-0002-7909-7719
Dessalegn Abeje TeferaArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Henok AndualemDepartment of Medical Laboratory Science, College of Medicine and Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.ORCID 0000-0001-6883-9548
Alene GetenehDepartment of Medical Laboratory Science, College of Health Sciences, Woldia University, Woldia, Ethiopia.ORCID 0000-0002-7153-4849
Abebech TesfayeArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Tamirayehu Seyoum WoldemichaelArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Eleni KidaneThe Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Dawit Hailu AlemayehuArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Melanie MaierDepartment Virology, Institute Medical Microbiology and Virology, Leipzig University, Leipzig, Germany.
Adane MihretArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Woldaregay Erku AbegazDepartment of Microbiology, Parasitology, and Immunology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Andargachew MuluArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Armauer Hansen Research Institute · ETAddis Ababa University · ETAksum University · ETDebre Tabor University · ETEthiopian Public Health Institute · ETLeipzig University · DEWoldia University · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the widespread use of Integrase strand transfer inhibitors (INSTIs), surveillance of HIV-1 pretreatment drug resistance is critical in optimizing antiretroviral treatment efficacy. However, despite the introduction of these drugs, data concerning their resistance mutations (RMs) is still limited in Ethiopia. Thus, this study aimed to assess INSTI RMs and polymorphisms at the gene locus coding for Integrase (IN) among viral isolates from ART-naive HIV-1 infected Ethiopian population. This was a cross-sectional study involving isolation of HIV-1 from plasma of 49 newly diagnosed drug-naive HIV-1 infected individuals in Addis-Ababa during the period between June to December 2018. The IN region covering the first 263 codons of blood samples was amplified and sequenced using an in-house assay. INSTIs RMs were examined using calibrated population resistance tool version 8.0 from Stanford HIV drug resistance database while both REGA version 3 online HIV-1 subtyping tool and the jumping profile Hidden Markov Model from GOBICS were used to examine HIV-1 genetic diversity. Among the 49 study participants, 1 (1/49; 2%) harbored a major INSTIs RM (R263K). In addition, blood specimens from 14 (14/49; 28.5%) patients had accessory mutations. Among these, the M50I accessory mutation was observed in a highest frequency (13/49; 28.3%) followed by L74I (1/49; 2%), S119R (1/49; 2%), and S230N (1/49; 2%). Concerning HIV-1 subtype distribution, all the entire study subjects were detected to harbor HIV-1C strain as per the IN gene analysis. This study showed that the level of primary HIV-1 drug resistance to INSTIs is still low in Ethiopia reflecting the cumulative natural occurrence of these mutations in the absence of selective drug pressure and supports the use of INSTIs in the country. However, continues monitoring of drug resistance should be enhanced since the virus potentially develop resistance to this drug classes as time goes by.

Indexed as

Drug Resistance, NeoplasmDrug Resistance, ViralHIV-1HIV InfectionsHIV IntegraseHIV Integrase InhibitorsCross-Sectional StudiesEast African PeopleGenotypeHIV SeropositivityHumansMutationHIV IntegraseHIV Integrase Inhibitors

Identifiers

PMID37085698
PMCPMC10121640
OpenAlexW4366742310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.